Acotec Scientific Holdings Limited (HK:6669)
:6669
Want to see HK:6669 full AI Analyst Report?
6669 Stock Chart & Stats
HK$14.16
-HK$0.14(-2.42%)
At close: 4:00 PM EST
HK$14.16
-HK$0.14(-2.42%)
Day’s Range― - ―
52-Week RangeHK$7.07 - HK$15.47
Previous CloseN/A
Volume343.13K
Average Volume (3M)462.19K
Market Cap
HK$2.82B
Enterprise ValueHK$2.25B
Total Cash (Recent Filing)HK$995.38M
Total Debt (Recent Filing)HK$236.13M
Price to Earnings (P/E)31.1
Beta1.02
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.34
Shares Outstanding313,389,160
10 Day Avg. Volume400,669
30 Day Avg. Volume462,190
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.51
Price to Sales (P/S)5.75
P/FCF Ratio25.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$17.00Price Target Upside20.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.45
Revenue Forecast (FY)HK$732.25M
Bulls Say, Bears Say
Bulls Say
High Gross And Improving Net MarginsSustained gross margin (~72%) combined with a step-up in net margin to ~18.5% indicates durable product-level profitability and improved operating leverage. That margin base supports long-term cash generation, reinvestment in R&D/sales, and resilience versus procedure-volume swings.
Stronger Cash Generation And Free Cash FlowMaterial improvement in OCF and FCF, with FCF covering ~87% of net income, reflects better cash conversion and operational discipline. Durable cash generation underpins capacity to fund working capital, capex and product commercialization without heavy reliance on external financing.
Conservative Balance Sheet And Improved Capital BaseLow leverage (D/E ~0.17) and a repaired equity base provide financial flexibility to support growth, M&A, or downturns. The combination of asset/equity growth and rising ROE signals improving capital efficiency and a stronger foundation for multi-year expansion.
Bears Say
Historical Earnings Volatility And Prior LossesThe firm experienced losses in 2020–2021 and a sharp earnings dip in 2023, showing earnings are not yet cycle-proof. Persistent volatility raises execution risk for scaling sales, sustaining margins, and delivering consistent returns to shareholders over multiple quarters.
Uneven Free Cash Flow TrendDespite recent FCF levels, declining FCF in 2025 and prior negative OCF/FCF episodes highlight uncertainty in long-term cash consistency. That unevenness can limit predictable reinvestment, constrain working capital flexibility, and complicate capital allocation decisions.
Moderate Returns Relative To Higher-quality PeersROE near 7.9% signals improving but still-moderate capital efficiency. If peers deliver materially higher ROEs, Acotec may struggle to match return expectations without sustained margin expansion, faster revenue growth, or more efficient capital deployment.
Acotec Scientific Holdings Limited News
6669 FAQ
What was Acotec Scientific Holdings Limited’s price range in the past 12 months?
Acotec Scientific Holdings Limited lowest stock price was HK$7.07 and its highest was HK$15.47 in the past 12 months.
What is Acotec Scientific Holdings Limited’s market cap?
Acotec Scientific Holdings Limited’s market cap is HK$2.82B.
When is Acotec Scientific Holdings Limited’s upcoming earnings report date?
Acotec Scientific Holdings Limited’s upcoming earnings report date is Sep 02, 2026 which is in 103 days.
How were Acotec Scientific Holdings Limited’s earnings last quarter?
Acotec Scientific Holdings Limited released its earnings results on Mar 26, 2026. The company reported HK$0.112 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.112.
Is Acotec Scientific Holdings Limited overvalued?
According to Wall Street analysts Acotec Scientific Holdings Limited’s price is currently Undervalued.
Does Acotec Scientific Holdings Limited pay dividends?
Acotec Scientific Holdings Limited does not currently pay dividends.
What is Acotec Scientific Holdings Limited’s EPS estimate?
Acotec Scientific Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acotec Scientific Holdings Limited have?
Acotec Scientific Holdings Limited has 313,389,160 shares outstanding.
What happened to Acotec Scientific Holdings Limited’s price movement after its last earnings report?
Acotec Scientific Holdings Limited reported an EPS of HK$0.112 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.51%.
Which hedge fund is a major shareholder of Acotec Scientific Holdings Limited?
Currently, no hedge funds are holding shares in HK:6669
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acotec Scientific Holdings Limited
Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease; under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications; and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, which is under registration process in China and Europe, and under preclinical studies in the United States in vascular surgery for below-the-knee artery disease indications/applications; and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited is a subsidiary of CA Medtech Investment (Cayman) Limited.
6669 Stock 12 Month Forecast
Average Price Target
HK$17.00
▲(20.06% Upside)
Technical Analysis
Peijia Medical Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Venus Medtech (Hangzhou), Inc. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―
Options Prices
Currently, No data available
---